AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Novartis AG Director's Dealing 2018

Aug 6, 2018

940_dirs_2018-08-06_5e40bb5d-60ef-4dfe-8a80-666115602b97.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AILERON THERAPEUTICS INC (ALRN)
CIK: 0001420565
Period of Report: 2018-08-02

Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-02	Common Stock	S	4702	$3.33	Disposed	2453844	Direct

Footnotes

F1: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.